ClinicalTrials.gg
Not yet recruitingNCT07507071pCLEUpdated Apr 2, 2026

Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions

An observational study in Early Gastric Cancer, sponsored by Changhai Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Changhai Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-crossover
Time perspective
Retrospective
Enrollment
169
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Stomach Neoplasms by Changhai Hospital — 4 open to participants now, 4 under way, none of them phase 3. Stomach Neoplasms · Changhai Hospital.

Started
2026
the only one that year
Observational
4 of 10
2 open now
Registered
10th of 10
by date

Among the 10 studies in Stomach Neoplasms by Changhai Hospital, this one is the only one that started in 2026, is one of 4 observational ones, and was the 10th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

4 of the 10 studies in Stomach Neoplasms by Changhai Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Stomach Neoplasms by Changhai Hospital, or all of them as a file.
02

Study summary

The pathological biopsy of gastric lesions, performed prior to endoscopic submucosal dissection (ESD), is crucial for differentiating the pathological nature of the lesions and guiding treatment decisions. However, due to the impact of biopsy sampling, the sensitivity of the pathological biopsy is not optimal.

The probe - based confocal laser endomicroscopy (pCLE) technique enables the real - time display of high-resolution microscopic images of the mucosal layer (with an amplification factor of up to 1000 times) through a slender optical fiber probe that can pass through the standard endoscope's working channel. It is an optical biopsy technique and has unique value in determining the pathological nature of gastric lesions.

As the Digestive Endoscopy Center of Shanghai Changhai Hospital is a national-level pCLE application demonstration center, it has prospectively collected numerous cases of pCLE examinations of gastric mucosal lesions.

The main purpose of this study is to retrospectively analyze these cases and compare the sensitivity and specificity of pathological biopsy and pCLE in differentiating the pathological nature of gastric mucosal lesions.

Read the detailed description

In this study, the pathological results of ESD or surgical resection of large specimens were used as the gold standard. The sensitivity of preoperative confocal endomicroscopy examination and pathological biopsy for gastric mucosal cancerous lesions was compared. The study adopted a retrospective approach and invited three experts to conduct offline blind diagnoses of the confocal endoscopy images respectively. First, two experts independently diagnosed all the cases. For those cases with inconsistent diagnosis results, a third expert was then consulted for a final determination. Although it was a retrospective study, the cases included in the research were all prospectively and continuously included in a demonstration project.

03

Conditions studied

  • Early Gastric Cancer

Browse trials for

Keywords

  • Pathological biopsy
  • Early gastric cancer
  • High-grade intraepithelial neoplasia
  • Probe-based confocal Laser endomicroscopy
  • Endoscopic submucosal dissection
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population primarily consisted of patients who had undergone both preoperative pathological biopsy and pCLE examination and then received endoscopic submucosal dissection (ESD) treatment. As both pathological biopsy and pCLE struggle to achieve a perfect diagnosis, this study employed the pathological diagnosis obtained via ESD surgery as the gold standard to compare the sensitivity, specificity, and accuracy of pathological biopsy and pCLE in diagnosing early gastric cancer.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients aged 18-75 who underwent pCLE examination and received ESD treatmen.

Exclusion criteria

Exclusion Criteria:

  • lack of pre-ESD pathological results, and ESD pathology indicated advanced gastric cancer.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Case-crossover
Time perspective
Retrospective
Enrollment
169 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • Diagnostic testProbe-based Confocal Laser Endomicroscopy

    Description: Confocal Laser Endomicroscopy (CLE) is an advanced in vivo imaging technique that combines confocal microscopy with endoscopy, enabling real-time, microscopic visualization of tissues at a cellular level during endoscopic procedures. Probe-based CLE (pCLE) can enter the stomach cavity through the biopsy channel of the endoscope and observe the gastric mucosa. All patients scheduled for endoscopic submucosal dissection (ESD) of gastric lesions must undergo probe-based confocal laser endomicroscopy (pCLE) prior to the ESD procedure.

    Also known as: Optical biopsy

  • Diagnostic testPathological biopsy

    A pathological biopsy is a medical procedure that involves the removal of a small sample of tissue or cells from the body for microscopic examination. It is a crucial diagnostic tool used to identify diseases, particularly cancer, infections, inflammatory conditions, and other abnormalities.

06

What researchers measure

Primary outcomes

  1. Sensitivity

    Sensitivity, also known as True Positive Rate (TPR), refers to the proportion of patients with early gastric cancer that can be correctly identified by a certain diagnostic technique. High sensitivity means that this detection method can minimize the risk of missed diagnoses to the greatest extent and is applicable for disease screening (such as infectious diseases and early cancer screening).

    Time frame: The pathological results can be obtained within 10 working days after ESD treatment, which can be used for sensitivity calculation.

Secondary outcomes

  1. Specificity

    Specificity refers to the ability of a diagnostic test to accurately identify individuals without early gastric cancer (true negative, TN), namely, the proportion of individuals who are actually healthy and test negative.

    Time frame: The pathological results can be obtained within 10 working days after ESD treatment, which can be used for specific calculations.

  2. Accuracy

    Accuracy refers to a comprehensive indicator that measures the ability of a medical test or diagnostic method to correctly distinguish between early gastric cancer and non - cancerous lesions. It is the ratio of the sum of true positives and true negatives to the total test population.

    Time frame: The pathological results can be obtained within 10 working days after ESD treatment, which can be used for the calculation of accuracy.

  3. Positive Predictive Value (PPV)

    PPV is an important indicator in diagnostic tests, used to assess the probability that a subject actually has early gastric cancer when the test result is positive. Here is a detailed explanation.

    Time frame: The pathological results can be obtained within 10 working days after ESD treatment, which can be used for sensitivity calculation.

  4. Nnegative predictive value (NPV)

    The definition of NPV is the probability that a lesion diagnosed as a non-cancerous lesion is actually non-cancerous.

    Time frame: The pathological results can be obtained within 10 working days after ESD treatment, which can be used for sensitivity calculation.

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — The data that support the findings of this study are available from the corresponding author upon reasonable request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Apr 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Apr 2, 2026
StartEst.
Mar 30, 2026
Primary completionEst.
Apr 10, 2026
CompletionEst.
Apr 15, 2026
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07507071
Lead sponsor
Changhai Hospital
Responsible party
Zhaoshen Li (Department of Gastroenterology, Changhai Hospital) — Principal investigator
First posted
Apr 2, 2026
Start date
Mar 30, 2026 (estimated)
Primary completion
Apr 10, 2026 (estimated)
Completion
Apr 15, 2026 (estimated)
Last update
Apr 2, 2026

Study contacts

Zhaoshen Li, Ph.D
Contact
li.zhaoshen@hotmail.com
+8618936364880
Peng Pan, M.D
Contact
li.zhaoshen@hotmail.com
+8618721828503

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion